|
|
- Denosumab (subcutaneous route) - Side effects uses
Denosumab injection is used to treat osteoporosis (thinning of the bones) in women who have an increased risk for fractures after menopause, and osteoporosis in men It is given when other medicines cannot be used or after other medicines did not work well
- Denosumab - Wikipedia
Denosumab inhibits this maturation of osteoclasts by binding to and inhibiting RANKL Denosumab mimics the natural action of osteoprotegerin, an endogenous RANKL inhibitor, that presents with decreasing concentrations (and perhaps decreased effectiveness) in people with osteoporosis
- Prolia Injection (Denosumab): Uses Side Effects
Prolia® injection is a brand of denosumab, which treats osteoporosis Osteoporosis is a condition that weakens your bones, making them more susceptible to fractures
- Denosumab (Prolia, Jubbonti, Stoboclo): Uses, Side Effects . . . - WebMD
What is denosumab used for? Denosumab (Prolia, Jubbonti, Stoboclo) is commonly used to treat osteoporosis, a condition in which the bones are thinner, weaker, and more prone to breakage
- Denosumab for osteoporosis - UpToDate
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor kappa-B ligand (RANKL), an osteoclast differentiating factor It inhibits osteoclast formation, decreases bone resorption, increases bone mineral density (BMD), and reduces the risk of fracture
- Denosumab (Xgeva®, Prolia®) - Macmillan Cancer Support
Denosumab (XGEVA®, Prolia®) is a targeted therapy drug It is used to strengthen and protect the bones from the effect of cancer or cancer treatment
- Denosumab Injection: MedlinePlus Drug Information
Denosumab injection is in a class of medications called RANK ligand inhibitors It works to prevent bone loss by blocking a certain receptor in the body to decrease bone breakdown
- Denosumab for osteoporosis treatment: when, how, for whom, and for how . . .
Denosumab, a monoclonal antibody against the receptor activator of nuclear factor κ-Β ligand (RANKL), is a powerful antiresorptive agent Denosumab was approved by European and US regulatory authorities in 2010 The dose approved for osteoporosis is 60 mg administered subcutaneously every 6 months
- Denosumab: Side Effects, Uses, Dosage, Interactions, Warnings - RxList
Denosumab is a human IgG2 monoclonal antibody used to treat bone problems that may occur with cancer that has spread (metastasized) to the bones Learn about side effects, dosages, drug interactions, and more
|
|
英文每年常用名排名
2024 年排名
2023 年排名
2022 年排名
2021 年排名
2020 年排名
2019 年排名
2018 年排名
2017 年排名
2016 年排名
2015 年排名
2014 年排名
2013 年排名
2012 年排名
2011 年排名
2010 年排名
2009 年排名
2008 年排名
2007 年排名
2006 年排名
2005 年排名
2004 年排名
2003 年排名
2002 年排名
2001 年排名
英文名字起源
希伯來
希臘
條頓
印度
拉丁
拉丁語
古英語
英格蘭
阿拉伯
法國
蓋爾
英語
匈牙利
凱爾特
西班牙
居爾特
非洲
美洲土著
挪威
德國
威爾士
斯拉夫民族
古德語
愛爾蘭
波斯
古法語
盎格魯撒克遜
意大利
蓋爾語
未知
夏威夷
中古英語
梵語
蘇格蘭
俄羅斯
土耳其
捷克
希臘;拉丁
斯干那維亞
瑞典
波蘭
烏干達
拉丁;條頓
巴斯克語
亞拉姆
亞美尼亞
斯拉夫語
斯堪地納維亞
越南
荷蘭
|